Cytokine Dynamics in Non-Small Cell Lung Cancer

Cytokines are small secreted proteins that mediate communication between immune cells, stromal elements and tumour cells. In non-small cell lung cancer (NSCLC), a complex network of pro- and anti-inflammatory cytokines shapes tumour initiation, progression and response to therapy. Within the tumour microenvironment, elevated levels of interleukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor-α (TNF-α) can promote angiogenesis, recruit immunosuppressive myeloid-derived suppressor cells and skew macrophages towards a tumour-supportive phenotype. Conversely, interferon-γ (IFN-γ) and certain chemokines enhance cytotoxic T-cell infiltration and augment antigen presentation. Systemic cytokine profiles also reflect intratumoral immune activity and may serve as minimally invasive biomarkers. Dynamic monitoring of circulating cytokines alongside emerging liquid-biopsy approaches—including circulating tumour DNA and immune cell subsets—offers a holistic view of evolving immune dynamics. Unraveling the interplay between cytokine networks, checkpoint inhibitor efficacy and mechanisms of resistance is critical for refining patient stratification and guiding combination immunotherapies in a globally prevalent malignancy.

Research from Nature Portfolio

Recent studies have demonstrated that baseline systemic inflammation and cytokine signatures can predict response to single-agent PD-1 blockade in advanced NSCLC. Patients with elevated neutrophil-to-lymphocyte ratios and high pre-treatment concentrations of IL-6 and IL-8 exhibited lower response rates and shorter progression-free survival, whereas higher levels of IFN-γ characterised a subgroup with durable benefit. Longitudinal sampling revealed that low systemic inflammation combined with elevated IFN-γ defined patients achieving long-term disease control. These findings underscore the potential of integrating peripheral cytokine profiling into clinical decision-making to anticipate checkpoint inhibitor outcomes and tailor immunotherapeutic strategies.

Cytokine Dynamics in Non-Small Cell Lung Cancer publication trend

The graph below shows the total number of articles in cytokine dynamics in non-small cell lung cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Cytokine: A low-molecular-weight protein secreted by immune or tumour cells to regulate inflammation and cell communication.

NSCLC (Non-Small Cell Lung Cancer): The most common form of lung cancer, comprising several histological subtypes with distinct molecular profiles.

Tumour Microenvironment: The complex milieu of cancer cells, immune cells, stromal cells and extracellular matrix surrounding a tumour.

Immune Checkpoint Inhibitors (ICIs): Therapeutic antibodies that release inhibitory brakes on T cells by targeting molecules such as PD-1 and CTLA-4.

Pro-inflammatory Cytokines: A subset of cytokines (e.g., IL-6, IL-8, TNF-α) that promote inflammatory responses and can support tumour progression.

Liquid Biopsy: A minimally invasive method to sample circulating tumour components and immune markers from blood for dynamic disease monitoring.

References

1. Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. Journal of Experimental & Clinical Cancer Research (2024).
2. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study. Scientific Reports (2021).
3. Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12. Frontiers in Immunology (2023).
4. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Medicine (2022).